603538 Stock Overview
Research, develops, produces, and sells pharmaceutical products.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 5/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
Ningbo Menovo Pharmaceutical Co., Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CN¥10.89 |
52 Week High | CN¥22.02 |
52 Week Low | CN¥9.96 |
Beta | 0.065 |
11 Month Change | -2.59% |
3 Month Change | -15.19% |
1 Year Change | -29.29% |
33 Year Change | -51.35% |
5 Year Change | -26.04% |
Change since IPO | -9.62% |
Recent News & Updates
Shareholder Returns
603538 | CN Pharmaceuticals | CN Market | |
---|---|---|---|
7D | -10.5% | -2.9% | -2.8% |
1Y | -29.3% | -10.1% | -18.4% |
Return vs Industry: 603538 underperformed the CN Pharmaceuticals industry which returned -10.1% over the past year.
Return vs Market: 603538 underperformed the CN Market which returned -18.4% over the past year.
Price Volatility
603538 volatility | |
---|---|
603538 Average Weekly Movement | 4.8% |
Pharmaceuticals Industry Average Movement | 5.2% |
Market Average Movement | 5.6% |
10% most volatile stocks in CN Market | 8.9% |
10% least volatile stocks in CN Market | 3.7% |
Stable Share Price: 603538's share price has been volatile over the past 3 months.
Volatility Over Time: 603538's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2004 | 2,353 | Cheng Zhi Yao | www.menovopharm.com |
Ningbo Menovo Pharmaceutical Co., Ltd. research, develops, produces, and sells pharmaceutical products. The company’s products portfolio includes valsartan, losartan, clopidogrel, perindopril, rosuvastatin calcium, atorvastatin calcium, purin bahrain, and other products. It offers APIs, intermediates, and preparations for the treatment of cardiovascular, central nervous system, gastrointestinal tract, and other therapeutic areas.
Ningbo Menovo Pharmaceutical Co., Ltd. Fundamentals Summary
603538 fundamental statistics | |
---|---|
Market cap | CN¥2.38b |
Earnings (TTM) | -CN¥17.82m |
Revenue (TTM) | CN¥1.23b |
1.9x
P/S Ratio-133.7x
P/E RatioIs 603538 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
603538 income statement (TTM) | |
---|---|
Revenue | CN¥1.23b |
Cost of Revenue | CN¥872.24m |
Gross Profit | CN¥360.70m |
Other Expenses | CN¥378.52m |
Earnings | -CN¥17.82m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 31, 2024
Earnings per share (EPS) | -0.081 |
Gross Margin | 29.26% |
Net Profit Margin | -1.45% |
Debt/Equity Ratio | 57.5% |
How did 603538 perform over the long term?
See historical performance and comparison